Expression of the Antiapoptosis Gene Survivin Predicts Poor Prognosis of Stage III Gastric Adenocarcinoma

被引:34
作者
Song, Kyo Young [1 ]
Jung, Chan Kwon [2 ]
Park, Won Sang [3 ]
Park, Cho Hyun [1 ]
机构
[1] Catholic Univ Korea, Div Gastrointestinal Surg, Coll Med, Dept Surg, Seoul 137701, South Korea
[2] Catholic Univ Korea, Coll Med, Dept Hosp Pathol, Seoul 137701, South Korea
[3] Catholic Univ Korea, Coll Med, Dept Pathol, Seoul 137701, South Korea
关键词
survivin; antiapoptosis; inhibitors of apoptosis proteins; prognosis; Stage III gastric cancer; ANTI-APOPTOSIS GENE; CANCER PATIENTS; CELL-SURVIVAL; P53; CARCINOMA; INHIBITOR; BCL-2;
D O I
10.1093/jjco/hyp020
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study was designed to determine the level of survivin expression and its clinical significance as a prognostic factor in Stage III gastric adenocarcinoma. We performed immunohistochemical staining for survivin, p53 and Bax in formalin-fixed, paraffin-embedded blocks from 157 surgically resected Stage III gastric cancer tissues. To determine the association with clinical course, we reviewed the patients' clinical records. Of the 157 gastric cancer tissues, 63 (40.1%) cases showed positive expression for survivin protein. There was no significant association between survivin expression and p53 or Bax. For clinicopathologic parameters, large tumor size was closely related to survivin expression (P < 0.05). The 5-year survival rate of patients with positive survivin expression was significantly lower compared with that for survivin-negative cancer patients (P < 0.05). Survivin and p53 were independent prognostic factors in Stage III gastric cancer. Survivin protein is an important predictive and prognostic parameter of poor outcome in gastric carcinoma.
引用
收藏
页码:290 / 296
页数:7
相关论文
共 33 条
[1]  
Adida C, 1998, AM J PATHOL, V152, P43
[2]   Targeted therapy by disabling crossroad signaling networks:: the survivin paradigm [J].
Altieri, DC .
MOLECULAR CANCER THERAPEUTICS, 2006, 5 (03) :478-482
[3]   Molecular markers for gastric adenocarcinoma - An update [J].
Anderson, Casandra ;
Nijagal, Amar ;
Kim, Joseph .
MOLECULAR DIAGNOSIS & THERAPY, 2006, 10 (06) :345-352
[4]   Gastric adenocarcinoma - Review and considerations for future directions [J].
Dicken, BJ ;
Bigam, DL ;
Cass, C ;
Mackey, JR ;
Joy, AA ;
Hamilton, SM .
ANNALS OF SURGERY, 2005, 241 (01) :27-39
[5]   Advances in the treatment of patients with gastric adenocarcinoma [J].
Foukakis, Theodoros ;
Lundell, Lars ;
Gubanski, Michael ;
Lind, Pehr A. .
ACTA ONCOLOGICA, 2007, 46 (03) :277-285
[6]   Targeting p53 to mitochondria for cancer therapy [J].
Galluzzi, Lorenzo ;
Morselli, Eugenia ;
Kepp, Oliver ;
Tajeddine, Nicolas ;
Kroemer, Guido .
CELL CYCLE, 2008, 7 (13) :1949-1955
[7]   High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma [J].
Islam, A ;
Kageyama, H ;
Takada, N ;
Kawamato, T ;
Takayasu, H ;
Isogai, E ;
Ohira, M ;
Hashizume, K ;
Kobayashi, H ;
Kaneko, Y ;
Nakagawara, A .
ONCOGENE, 2000, 19 (05) :617-623
[8]   Survivin promotes cell proliferation in human hepatocellular carcinoma [J].
Ito, T ;
Shiraki, K ;
Sugimoto, K ;
Yamanaka, T ;
Fujikawa, K ;
Ito, M ;
Takase, K ;
Moriyama, M ;
Kawano, H ;
Hayashida, M ;
Nakano, T ;
Suzuki, A .
HEPATOLOGY, 2000, 31 (05) :1080-1085
[9]  
Japanese Gastric Cancer Association, 1998, Gastric Cancer, V1, P10
[10]   Survivin: A bifunctional inhibitor of apoptosis protein [J].
Johnson, ME ;
Howerth, EW .
VETERINARY PATHOLOGY, 2004, 41 (06) :599-607